On December 13, 2017 Cascadian Therapeutics, Inc. (Nasdaq:CASC), a clinical-stage biopharmaceutical company, reported that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI), which will become effective prior to U.S. market open on Monday, December 18, 2017 (Press release, Cascadian Therapeutics, DEC 13, 2017, View Source [SID1234522627]).

The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on the Nasdaq Stock Market (Nasdaq) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The Nasdaq Biotechnology Index is re-ranked annually and all securities in the index are listed on the Nasdaq Global Market or the Nasdaq Global Select Market, and meet minimum market value and share volume requirements among other criteria. For more information about the Nasdaq Biotechnology Index, including eligibility criteria, visit www.nasdaq.com.